Who
Craig B. Granowitz
SVP, Chief Medical Officer
Company insider
Files Form 4 as: SVP, Chief Medical Officer, Lexicon Pharmaceuticals.
In numbers
- Trades disclosed
- 42
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Aug 2021
- Last trade
- 28 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —35,790 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —74,226 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —202,260 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,790 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —74,226 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —202,260 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $160K109,098 at $1.47 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,790 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —74,226 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —202,260 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —35,790 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —74,226 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —202,260 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $160K109,098 at $1.47 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —346,610 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —519,920 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —346,610 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —519,920 at $0.00 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,917 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,790 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.